Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 6,861 matching trials from the live ClinicalTrials.gov search.

Filters: Orlando, Florida Clear all

Conditions: Diabetes
Interventions: Thymosin Beta 4 (Tβ4), Placebo; Drug · Other
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Inglewood, California • Los Angeles, California • Orlando, Florida + 2 more

Conditions: COVID-19
Interventions: AT-527, Placebo; Drug · Other
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Scottsdale, Arizona • Davis, California • Los Angeles, California + 11 more

Conditions: Type-2 Diabetes
Interventions: vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more

Conditions: Type II Diabetes Mellitus
Interventions: GL0034; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 3
States / cities: Miami, Florida • Miami Lakes, Florida • Orlando, Florida

Conditions: Chronic Pain
Interventions: Hydrocodone ER; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 54
States / cities: Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more

Conditions: Alzheimer Disease, Early Onset Alzheimer Disease
Interventions: LX1001; Biological
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Maitland, Florida • Orlando, Florida • New York, New York + 1 more

Conditions: Graves' Disease
Interventions: IMVT-1402; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 89
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 75 more

Conditions: Stage III Non-small Cell Lung Cancer, Unresectable
Interventions: Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 28
States / cities: Anaheim, California • Duarte, California • Sacramento, California + 24 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: CP-461; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Orlando, Florida • Albany, New York • Dallas, Texas + 2 more

Conditions: Colorectal Cancer, Breast Cancer, Healthy
Interventions: Not listed
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV-1-Infection
Interventions: ISL/LEN, Antiretroviral Combinations; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more

Conditions: Healthy Volunteer
Interventions: RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Emphysema
Interventions: EBV, Optimal Medical Management; Device · Other
Lead sponsor: Pulmonx Corporation; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more

Conditions: Influenza, Human
Interventions: mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 54,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 161
States / cities: Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more

Conditions: Crohn's Disease
Interventions: vedolizumab, Placebo; Drug · Other
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 110
States / cities: Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more

Conditions: Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: management of therapy complications; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 73
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Graves' Disease
Interventions: IMVT-1402, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 64
States / cities: Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more

Conditions: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 91
States / cities: Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more

Conditions: COVID-19
Interventions: VYD2311-SD, VYD2311-MD, Placebo; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 1,770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 20
States / cities: Long Beach, California • San Diego, California • Orlando, Florida + 17 more

Conditions: Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions: sargramostim, quality-of-life assessment, radiation therapy; Biological · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 217
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more

Conditions: Major Depressive Disorder
Interventions: DVS SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 33
States / cities: Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more

Conditions: Ependymoma, Recurrent Childhood, Ependymoma
Interventions: Granulocyte Macrophage Colony Stimulation Factor; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Months to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Denver, Colorado • Orlando, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Phoenix, Arizona • Anaheim, California • Greenbrae, California + 39 more

Search by objective public record fields.

A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Tumor-Derived FGF19

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Study of VYD2311 for the Prevention of COVID-19

Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Study of the Effect of GM-CSF on Macrophages in Ependymoma

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes